Collaborative and Stepped Care in Mental Health (COMET)

Alcohol Use Disorder Clinical Trial

— COMET  

Official title:

Collaborative and Stepped Care in Mental Health by Overcoming Treatment Sector Barriers: A Cluster-randomized Controlled Trial (COMET)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03226743
• Other study ID #: 01GY1602
• Status: Completed
• Phase: N/A
• Start date: July 12, 2018
• Est. completion date: October 7, 2022

Study information

• Verified date: November 2022
• Source: Universitätsklinikum Hamburg-Eppendorf
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aims of COMET are the implementation and evaluation of effectiveness and cost-effectiveness as well as processes of a collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network in comparison to routine care. In a cluster-randomized controlled effectiveness trial 570 patients will be recruited by 38 general practitioner practices and followed with a prospective survey at four time points. The primary outcome is the change in health-related quality of life from baseline to 6-months follow-up. Secondary outcomes include disorder-specific symptom burden, response, remission, functional quality of life, cost-effectiveness, evaluation of processes and other clinical and psychosocial variables.

Description:

Aims are a) the implementation and outcome evaluation, b) the process evaluation, and c) the analysis of the cost-effectiveness of an innovative collaborative and stepped care model for patients with depressive, anxiety, somatoform and/or alcohol abuse disorders.

Its novelty is the integration of these four disorders into one model. This approach is based on a) the high comorbidity between these disorders, b) the fact that they share a common etiological and diag-nostic basis, c) that similar evidence-based treatment options exist for them (e.g., self-help and psychoeducation, psychotherapy, pharmacotherapy), and d) that health care providers need to manage them together very often.

The conceptual basis follows the principles of evidence-based medicine with a specific focus on guideline implementation and the principles of patient-centered care including access, coordination and continuity of care, patient information, patient involvement and empowerment. Based on a multi-professional cooperation of health care providers across different care sectors an integrated health care network consisting of general practitioners (GPs), mental health specialists (psychiatrists, psychotherapists) and inpatient facilities will be established. Evidence-based clinical practice guidelines and pathways of care with treatment options of varying intensity form the clinical and procedural basis of the network, including low-intensity treatments and e-mental health technologies.

The study is planned as a randomized controlled effectiveness trial of a consecutive sample of patients with depressive and/or anxiety and/or somatoform and/or alcohol abuse disorders drawn from primary care (GP practices) and followed with a prospective survey at four time points. The study is intended to recruit a total of 570 patients from 38 GP practices. A cluster-randomization at the level of participating GP practices divides GPs into the intervention group, where patients are treated within a multi-professional collaborative and stepped care approach (including low-intensity treatments, direct access to mental health specialists, inpatient care etc., COMET), and the control group, where patients receive standard care (treatment as usual, TAU). Data collection is carried out with questionnaires as well as telephone interviews at four time-standardized measurement points within one year (baseline, 3, 6, 12 and 24 months). Additionally, independent research assistants perform standardized diagnostic interviews (CIDI) with patients at baseline to allow an assessment of diagnostic validity.

The main research hypothesis is that the COMET model is more effective than TAU. Primary outcome is the change in health-related quality of life measured by the SF-36 mental health score from baseline to 6-months follow-up. Secondary outcomes include symptom burden of depressive, generalized anxiety, panic, somatoform and alcohol abuse syndromes (PHQ-9; GAD-7; PHQ-15; PHQ panic and alcohol abuse syndrome module; SSD-12), disorder-specific response and remission, functional quality of life (EQ-5D-5L), duration of untreated illness, and other clinical and psychosocial variables (outcome evaluation, Work Package 1). Furthermore, direct and indirect costs and the incremental cost-effectiveness ratio will be assessed (economic evaluation, Work Package 2). Finally, feasibility and acceptance of the COMET model as well as of the different treatment components are assessed, including the implementation process (process evaluation, Work Package 3). To this end, semi-structured interviews will be conducted at two measurement points, supplemented by standardized surveys among involved patients and providers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 615
• Est. completion date: October 7, 2022
• Est. primary completion date: April 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Inclusion criteria are a minimum age of 18, informed consent and one or more of the following positive ICD-10-diagnoses: depressive episode (F32), recurrent depressive disorder (F33), dysthymia (F34.1), agoraphobia (F40.0), social phobia (F40.1), panic disorder (F41.0), generalized anxiety disorder (F41.1), mixed anxiety and depressive disorder (F41.2), somatoform disorders (F45), and/or mental and behavioral disorders due to use of alcohol (F10.1, F.10.2)

Exclusion Criteria:

• Patients with insufficient knowledge of the German language, an acute psychosis or a health situation that does not allow questionnaire completion or patients already receiving current in- or outpatient psychiatric or psychotherapeutic care are excluded.

Related Conditions & MeSH terms

• Alcohol Use Disorder
• Alcoholism
• Anxiety Disorder
• Anxiety Disorders
• Depressive Disorder
• Disease
• Somatoform Disorder
• Somatoform Disorders

Intervention

Other:
• collaborative and stepped care model
Including elements: collaborative and stepped care of patients with mental disorders treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities initial training of participating health care providers formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders formalized ICD-diagnostics guideline-oriented treatment recommendations bibliotherapy or internet-based self-help for patient with mild to moderate disorders online referral platform case management for patients with severe disorders systematic and regular monitoring regular quality circles for participating health care providers

Locations

Country	Name	City	State
Germany	University Medical Center Hamburg	Hamburg

Sponsors (3)

Lead Sponsor	Collaborator
Universitätsklinikum Hamburg-Eppendorf	Center for Health Care Research Hamburg, Hamburg Center for Health Economics

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in health-related quality of life	measured with the Short Form Health Survey SF-36 mental health score	from baseline to 6 months and 12 and 24 months after baseline
Secondary	change in disorder-specific symptoms: depression	measured on the major depressive module of the Patient Health Questionnaire PHQ: PHQ-9	from baseline to 6 months and 12 and 24 months after baseline
Secondary	change in disorder-specific symptoms: panic	measured on the panic module of the Patient Health Questionnaire PHQ: PHQ-panic module	from baseline to 6 months and 12 and 24 months after baseline
Secondary	change in disorder-specific symptoms: generalized anxiety	measured on the generalized anxiety module of the Patient Health Questionnaire PHQ: GAD-7	from baseline to 6 months and 12 months and 24 months after baseline
Secondary	change in disorder-specific symptoms: somatoform syndrome PHQ	measured on the somatoform module of the Patient Health Questionnaire PHQ: PHQ-15	from baseline to 6 months and 12 and 24 months after baseline
Secondary	change in disorder-specific symptoms: somatoform syndrome SSD-12	measured on the Somatic Symptom Disorder-B SSD-12	from baseline to 6 months and 12 and 24 months after baseline
Secondary	change in disorder-specific symptoms: alcohol abuse disorder	measured on the Alcohol Use Disorders Identification Test: AUDIT	from baseline to 6 months and 12 and 24 months after baseline
Secondary	cost effectiveness: direct costs	will be assessed based on health care utilization, reduced productivity at work and work loss days measured by a modified version the Client Sociodemographic and Service Receipt Inventory (CSSRI). For the monetary valuation of resources, unit costs will be applied.	from baseline to 6 months and 12 and 24 months after baseline
Secondary	cost effectiveness: indirect costs	will be assessed based on health care utilization, reduced productivity at work and work loss days measured by a modified version the Client Sociodemographic and Service Receipt Inventory (CSSRI). Indirect costs will be calculated based on the human capital approach.	from baseline to 6 months and 12 and 24 months after baseline
Secondary	cost effectiveness: health effects	quality-adjusted life years (QALYs) will be calculated based on utilities derived from the EQ-5D-5L questionnaire	from baseline to 6 months and 12 and 24 months after baseline
Secondary	cost effectiveness: incremental cost-effectiveness	incremental cost-effectiveness ratios (ICER) will be calculated	from baseline to 6 months and 12 and 24 months after baseline
Secondary	cost effectiveness: acceptability	Cost-effectiveness acceptability curves (CEAC) will be calculated.	from baseline to 6 months and 12 and 24 months after baseline